AUY922
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adenocarcinoma of the Pancreas
Conditions
Adenocarcinoma of the Pancreas, Metastatic Disease
Trial Timeline
Jan 1, 2012 → Aug 1, 2013
NCT ID
NCT01484860About AUY922
AUY922 is a phase 2 stage product being developed by Novartis for Adenocarcinoma of the Pancreas. The current trial status is terminated. This product is registered under clinical trial identifier NCT01484860. Target conditions include Adenocarcinoma of the Pancreas, Metastatic Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01485536 | Phase 2 | Terminated |
| NCT01668173 | Phase 2 | Terminated |
| NCT01484860 | Phase 2 | Terminated |
| NCT01404650 | Phase 2 | Completed |
| NCT01124864 | Phase 2 | Completed |
| NCT01132625 | Phase 1 | Completed |
Competing Products
20 competing products in Adenocarcinoma of the Pancreas